Search research articles
Contact Us
Filters
Showing results (161-170 of 222) with videos related to
Page
of 23
Sort By:
Annals of Internal Medicine
|
February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
The Journal of Infectious Diseases
|
September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 9, 2022
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
Yijia Li, Linda J Harrison, Kara W Chew, et al.
The Journal of Infectious Diseases
|
January 20, 2011
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection
Amie L Meditz, Samantha MaWhinney, Amanda Allshouse, et al.
The New England Journal of Medicine
|
December 3, 2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2020
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens
Michael A Leonard, Zinhle Cindi, Yuki Bradford, et al.
Pathogens & Immunity
|
May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Katya C Corado, Kara W Chew, Mark J Giganti, et al.
Journal of Neurovirology
|
February 16, 2019
Progressive brain atrophy in chronically infected and treated HIV+ individuals
Talia M Nir, Neda Jahanshad, Christopher R K Ching, et al.
Neuroimage. Clinical
|
November 2, 2013
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment
Xue Hua, Christina P Boyle, Jaroslaw Harezlak, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 27, 2015
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy
Albert M Anderson, Jaroslaw Harezlak, Ajay Bharti, et al.
Page
of 23
Search research articles
Search
Showing results (161-170 of 222) with videos related to
Sort By:
Page
of 23
Annals of Internal Medicine
|
February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
The Journal of Infectious Diseases
|
September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 9, 2022
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
Yijia Li, Linda J Harrison, Kara W Chew, et al.
The Journal of Infectious Diseases
|
January 20, 2011
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection
Amie L Meditz, Samantha MaWhinney, Amanda Allshouse, et al.
The New England Journal of Medicine
|
December 3, 2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2020
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens
Michael A Leonard, Zinhle Cindi, Yuki Bradford, et al.
Pathogens & Immunity
|
May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Katya C Corado, Kara W Chew, Mark J Giganti, et al.
Journal of Neurovirology
|
February 16, 2019
Progressive brain atrophy in chronically infected and treated HIV+ individuals
Talia M Nir, Neda Jahanshad, Christopher R K Ching, et al.
Neuroimage. Clinical
|
November 2, 2013
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment
Xue Hua, Christina P Boyle, Jaroslaw Harezlak, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 27, 2015
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy
Albert M Anderson, Jaroslaw Harezlak, Ajay Bharti, et al.
Page
of 23